Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

Experimental Hematology

Volumn 38, Issue 1, 2010, Pages 20-26

  Poláková, Kateřina Machová ^a   Polívková, Václava ^a   Rulcová, Jana ^a   Klamová, Hana ^a   Jurček, Tomáš ^b   Dvořáková, Dana ^b   Žáčková, Daniela ^b   Pospíšil, Zdeněk ^c   Mayer, Jiří ^b   Moravcová, Jana ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 71249126613     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.10.003     Document Type: Article

References (19)

1. Cang S., and Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 1 (2008) 15
2. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center-A 4.5-year follow-up. Cancer 103 (2005) 1659-1669
3. Khorashad J.S., de Lavallade H., Apperley J.F., et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 26 (2008) 4806-4813
4. Gabert J., Beillard E., van der Velden V.H.J., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer Program. Leukemia 17 (2003) 2318-2357
5. Rulcova J., Zmekova V., Zemanova Z., Klamova H., and Moravcova J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 31 (2007) 483-491
6. Poláková K.M., Lopotova T., Klamova H., and Moravcova J. High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain. Leuk Res 32 (2008) 1236-1243
7. Branford S., and Hughes T. Detection of BCR-ABL mutation and resistance to imatinib mesylate. In: Iland H., Hertzberg M., and Marlton P. (Eds). Myeloid leukemia: methods and protocols (2005), Humana Press Inc., Totowa, NJ 93-106
8. Willis S.G., Lange T., Demehri S., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients; correlation with clonal cytogenetic evolution but not response to therapy. Blood 106 (2005) 2128-2137
9. Moravcova J., Zmekova V., Klamova H., et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leuk Res 28 (2004) 415-419
10. Polakova K.M., Zmekova V., Rulcova J., Klamova H., Zemanova Z., and Moravcova J. BCR-ABL mutations in chronic myeloid leukemia - Not only detection. Leuk Lymph 49 (2008) 1620-1622
11. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 27 (2009) 469-471
12. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102 (2003) 276-283
13. Soverini S., Martinelli G., Rosti G., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 23 (2005) 4100-4109
14. Marin D., Milojkovic D., Olavarria E., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008) 4437-4444
15. Quintás-Cardama A., Kantarjian H., Jones D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patiens with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 18 (2009) 6315-6321
16. Branford S., Rudzki Z., Parkinson I., et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 104 (2004) 2926-2932
17. Press R.D., Love Z., Tronnes A.A., et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107 (2006) 4250-4256
18. Kantarjian H., Schiffer C., Jones D., and Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111 (2008) 1774-1780
19. Press R.D., Willis S.G., Laudadio J., Mauro M.J., and Deininger M.W.N. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 114 (2009) 2598-2605